AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26715076 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy
Number of subjects: 202
Study 24720703 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-450/r-ombitasvir and dasabuvir with ribavirin (group A)
Number of subjects: 631
Study 24720703 — intervention group
Group type: COMPARATOR
Intervention: Matching placebos (group B)
Number of subjects: 631
Study 22157201 — intervention group
Group type: EXPERIMENTAL
Intervention: sequential TACE and RF ablation (n=69)
Number of subjects: 139
Study 22157201 — intervention group
Group type: COMPARATOR
Intervention: RF ablation alone (n=70)
Number of subjects: 139
Study 19539818 — intervention group
Group type: EXPERIMENTAL
Intervention: Group plus individual therapy
Number of subjects: 2380
Study 19539818 — intervention group
Group type: COMPARATOR
Intervention: Individual therapy only
Number of subjects: 2380
Study 17483363 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus cisplatin
Number of subjects: 170
Study 17483363 — intervention group
Group type: EXPERIMENTAL
Intervention: ERCC1 mRNA expression
Number of subjects: 170
Study 15531038 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal immunization with recombinant hepatitis B vaccine (3 doses)
Number of subjects: 100
Study 15531038 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular immunization with recombinant hepatitis B vaccine (3 doses)
Number of subjects: 100
Study 11555442 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) 6 mg/kg body weight
Number of subjects: 51
Study 11555442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 9555112 — intervention group
Group type: EXPERIMENTAL
Intervention: Broca's aphasics
Number of subjects: 0
Study 9555112 — intervention group
Group type: EXPERIMENTAL
Intervention: Wernicke's aphasics
Number of subjects: 0
Study 9555112 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 7892428 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol cues during conditioning sessions
Number of subjects: 12
Study 2979250 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg omeprazole
Number of subjects: 9
Study 2979250 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole
Number of subjects: 9
Study 29318751 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab (8 mg/kg) plus best supportive care (BSC)
Number of subjects: 26
Study 29318751 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care (BSC)
Number of subjects: 26
Study 27101503 — intervention group
Group type: EXPERIMENTAL
Intervention: Error group
Number of subjects: 1600
Study 27101503 — intervention group
Group type: COMPARATOR
Intervention: No-error group
Number of subjects: 1600
Study 25600905 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (2 g/day)
Number of subjects: 44
Study 25600905 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training + placebo
Number of subjects: 44
Study 25600905 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation + aerobic training
Number of subjects: 44
Study 25600905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 23664333 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily
Number of subjects: 699
Study 23664333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 699
Study 20080082 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (group A)
Number of subjects: 68
Study 20080082 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (group B)
Number of subjects: 68
Study 20080082 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 68
Study 18412728 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-emitting diode-based optical probe (OP) in group A (n = 96)
Number of subjects: 44
Study 18412728 — intervention group
Group type: COMPARATOR
Intervention: Light-emitting diode-based optical probe (OP) followed by root surface debridement in group B (n = 80)
Number of subjects: 44
Study 16442460 — intervention group
Group type: EXPERIMENTAL
Intervention: Current body image (BMI approximately 27.7)
Number of subjects: 185
Study 16442460 — intervention group
Group type: EXPERIMENTAL
Intervention: Desired body image (BMI approximately 27.7)
Number of subjects: 185
Study 16442460 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perception of being overweight and attempting weight-loss
Number of subjects: 185
Study 14522788 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpegged hydroxyapatite porous implants
Number of subjects: 0
Study 14522788 — intervention group
Group type: COMPARATOR
Intervention: Spherical alloplastic nonporous implants
Number of subjects: 0
Study 14522788 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegged hydroxyapatite implants
Number of subjects: 0
Study 14522788 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclera-covered hydroxyapatite implants
Number of subjects: 0
Study 14522788 — intervention group
Group type: EXPERIMENTAL
Intervention: Unwrapped porous polyethylene implants
Number of subjects: 0
Study 11194951 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-platin-based chemotherapy and irradiation
Number of subjects: 2000
Study 11194951 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin-based chemotherapy and irradiation
Number of subjects: 2000
Study 11194951 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiochemotherapy groups
Number of subjects: 2000
Study 8874988 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine phosphate (CP) acute treatment (6 g CP intravenously)
Number of subjects: 13
Study 8874988 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine phosphate (CP) short-term treatment (6 g CP daily for 4 days)
Number of subjects: 13
Study 8874988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 1303072 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluconolactone 14% in solution (Nuvoderm lotion)
Number of subjects: 150
Study 1303072 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% benzoyl peroxide lotion
Number of subjects: 150
Study 1303072 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 150
Study 3889396 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven days of ceftriaxone therapy
Number of subjects: 79
Study 3889396 — intervention group
Group type: COMPARATOR
Intervention: Ten days of ceftriaxone therapy
Number of subjects: 79
Study 31337003 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% povidone iodine eye drops (three day-prophylactic treatment before the injection)
Number of subjects: 507
Study 31337003 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three day-prophylactic treatment)
Number of subjects: 507
Study 29145589 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-min treatment video (The ABCDs of Needle Pain Management)
Number of subjects: 128
Study 29145589 — intervention group
Group type: COMPARATOR
Intervention: Placebo video
Number of subjects: 128
Study 27350174 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer
Number of subjects: 243
Study 27350174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 24740633 — intervention group
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Number of subjects: 48
Study 23036277 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate radiotherapy (either 50 Gy in 25 daily fractions or 40 Gy in 15 daily fractions)
Number of subjects: 707
Study 23036277 — intervention group
Group type: COMPARATOR
Intervention: No radiotherapy (delayed salvage treatment)
Number of subjects: 707
Study 19924121 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg nilotinib twice daily
Number of subjects: 119
Study 19924121 — intervention group
Group type: COMPARATOR
Intervention: 400 mg nilotinib once daily
Number of subjects: 119
Study 19924121 — intervention group
Group type: COMPARATOR
Intervention: 800 mg nilotinib once daily
Number of subjects: 119
Study 19924121 — intervention group
Group type: COMPARATOR
Intervention: nilotinib after a high-fat meal
Number of subjects: 119
Study 17910802 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 382
Study 17910802 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 382
Study 17910802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study 17910802 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine vs. Risperidone
Number of subjects: 382
Study 16082604 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily subcutaneous enoxaparin (1.5 mg/kg)
Number of subjects: 298
Study 16082604 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (5000 IU bolus and 1250 IU/hour intravenous infusion)
Number of subjects: 298
Study 12395027 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse prevention intervention
Number of subjects: 0
Study 12395027 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 9498940 — intervention group
Group type: EXPERIMENTAL
Intervention: Proventil HFA
Number of subjects: 565
Study 9498940 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventolin
Number of subjects: 565
Study 9498940 — intervention group
Group type: COMPARATOR
Intervention: HFA-134a placebo
Number of subjects: 565
Study 8556964 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone take-homes
Number of subjects: 14
Study 8556964 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone dose increases
Number of subjects: 14
Study 8556964 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra counseling
Number of subjects: 14
Study 2122711 — intervention group
Group type: EXPERIMENTAL
Intervention: High carnitine supplementation (48 mg carnitine.kg‐1.d‐1)
Number of subjects: 2
Study 2122711 — intervention group
Group type: COMPARATOR
Intervention: Control (without carnitine supplementation)
Number of subjects: 2
Study 722814 — intervention group
Group type: EXPERIMENTAL
Intervention: Fair-fight training for 3 weeks followed by a sexual enhancement format for 3 additional weeks
Number of subjects: 14
Study 722814 — intervention group
Group type: EXPERIMENTAL
Intervention: The opposite treatment sequence (sexual enhancement format for 3 weeks followed by fair-fight training for 3 additional weeks)
Number of subjects: 14
Study 722814 — intervention group
Group type: COMPARATOR
Intervention: No‐treatment control group
Number of subjects: 14
Study 31362772 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified gastric tube
Number of subjects: 70
Study 31362772 — intervention group
Group type: COMPARATOR
Intervention: Conventional gastric tube
Number of subjects: 70
Study 28198989 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education provided by nurses to COPD patients
Number of subjects: 0
Study 26231455 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 92
Study 26231455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 23601443 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmakinetic enucleation of the prostate (PKEP)
Number of subjects: 83
Study 23601443 — intervention group
Group type: COMPARATOR
Intervention: Transvesical open prostatectomy (OP)
Number of subjects: 83
Study 21331557 — intervention group
Group type: EXPERIMENTAL
Intervention: Merino wool graduated compression stocking
Number of subjects: 20
Study 19248860 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunch only enhanced
Number of subjects: 33
Study 19248860 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast and lunch enhanced
Number of subjects: 33
Study 19248860 — intervention group
Group type: COMPARATOR
Intervention: Control (no meals enhanced)
Number of subjects: 33
Study 16766979 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous compartment pressure monitoring for 36 hours
Number of subjects: 200
Study 16766979 — intervention group
Group type: COMPARATOR
Intervention: Usual postoperative observations (nonmonitored group)
Number of subjects: 200
Study 15362146 — intervention group
Group type: EXPERIMENTAL
Intervention: High attendance group (n = 26)
Number of subjects: 44
Study 11122893 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 11122893 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene
Number of subjects: 0
Study 11122893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9052359 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propafenone
Number of subjects: 50
Study 9052359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8104468 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupenthixol decanoate
Number of subjects: 0
Study 8104468 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopenthixol decanoate
Number of subjects: 0
Study 2439826 — intervention group
Group type: EXPERIMENTAL
Intervention: bopindolol 1-2 mg
Number of subjects: 14
Study 2439826 — intervention group
Group type: COMPARATOR
Intervention: metoprolol 100-200 mg
Number of subjects: 14
Study 2439826 — intervention group
Group type: EXPERIMENTAL
Intervention: bopindolol 1 mg daily
Number of subjects: 14
Study 2439826 — intervention group
Group type: EXPERIMENTAL
Intervention: bopindolol 8 mg once weekly
Number of subjects: 14
Study 3288140 — intervention group
Group type: COMPARATOR
Intervention: Cold blood aortic root cardioplegia (ARC)
Number of subjects: 20
Study 3288140 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold blood retrograde coronary sinus cardioplegia (RCSC)
Number of subjects: 20
Study 3288140 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative ventricular function (stroke work index versus EDVI)
Number of subjects: 20
Study 3288140 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative LV systolic function (end-systolic blood pressure versus end-systolic volume index)
Number of subjects: 20
Study 3288140 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative diastolic function (pulmonary capillary wedge pressure versus EDVI)
Number of subjects: 20
Study 30582610 — intervention group
Group type: COMPARATOR
Intervention: Control group (timing of dressing and staples removal)
Number of subjects: 920
Study 30582610 — intervention group
Group type: EXPERIMENTAL
Intervention: Clusters two to five (timing of dressing and staples removal)
Number of subjects: 920
Study 30582610 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) > 35 kg/m2
Number of subjects: 920
Study 30582610 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent cesarean delivery (CD)
Number of subjects: 920
Study 30582610 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm premature rupture of membranes (PPROM)
Number of subjects: 920
Study 30582610 — intervention group
Group type: EXPERIMENTAL
Intervention: Chorioamnionitis at delivery
Number of subjects: 920
Study 28816944 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) at 35 Hz for 10 minutes
Number of subjects: 20
Study 28816944 — intervention group
Group type: COMPARATOR
Intervention: Nonvibrated group (placebo)
Number of subjects: 20
Study 24842589 — intervention group
Group type: EXPERIMENTAL
Intervention: Web‐based family problem‐solving treatment
Number of subjects: 132
Study 24842589 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 132
Study 23644396 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial heat using a cervical moist‐heat pack (77 °C)
Number of subjects: 12
Study 23644396 — intervention group
Group type: COMPARATOR
Intervention: Sham using a cervical moist pack (room temperature at about 24 °C)
Number of subjects: 12
Study 23644396 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 12
Study 21792013 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 149
Study 21792013 — intervention group
Group type: COMPARATOR
Intervention: Platinum-based chemotherapy
Number of subjects: 149
Study 18996761 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU of VitD weekly after RYGB
Number of subjects: 60
Study 18996761 — intervention group
Group type: COMPARATOR
Intervention: No additional VitD after RYGB
Number of subjects: 60
Study 17043071 — intervention group
Group type: EXPERIMENTAL
Intervention: VT-mapping group
Number of subjects: 47
Study 17043071 — intervention group
Group type: COMPARATOR
Intervention: Substrate-mapping group
Number of subjects: 47
Study 17043071 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study 12735558 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal Symmetry aortic connector
Number of subjects: 107
Study 12735558 — intervention group
Group type: COMPARATOR
Intervention: Conventional suture technique
Number of subjects: 107
Study 10700684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscularly administered dexamethasone acetate (IM Dex) approximately 1.7 mg/kg
Number of subjects: 32
Study 10700684 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone (PO Pred) approximately 2 mg/kg/d for 5 days
Number of subjects: 32
Study 10700684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscularly administered dexamethasone acetate (IM Dex)
Number of subjects: 32
Study 10700684 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone (PO Pred)
Number of subjects: 32
Study 9085957 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine test dose (15 microg) administered prior to spinal anesthesia
Number of subjects: 12
Study 9085957 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine test dose (15 microg) administered 30 min after injection of spinal anesthesia
Number of subjects: 12
Study 9085957 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine test dose (15 microg) administered at regression of sensory block to T-10
Number of subjects: 12
Study 7682388 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant M-VAC chemotherapy
Number of subjects: 49
Study 7682388 — intervention group
Group type: COMPARATOR
Intervention: Total cystectomy alone
Number of subjects: 49
Study 7682388 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative M-VAC chemotherapy
Number of subjects: 49
Study 3947233 — intervention group
Group type: EXPERIMENTAL
Intervention: LeVeen peritoneovenous shunt (LPVS)
Number of subjects: 22
Study 3947233 — intervention group
Group type: COMPARATOR
Intervention: Denver peritoneovenous shunt (DPVS)
Number of subjects: 22
Study 27806212 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatments for ADHD
Number of subjects: 148
Study 26905792 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic information application (app)
Number of subjects: 62
Study 26905792 — intervention group
Group type: COMPARATOR
Intervention: Control group (without the app)
Number of subjects: 62
Study 25633158 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 1% (DSG 1%)
Number of subjects: 0
Study 25633158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23763115 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention intervention
Number of subjects: 0
Study 23763115 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 20413514 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased moderate-to-vigorous leisure-time physical activity (LTPA)
Number of subjects: 486
Study 20413514 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (median 51 times/year)
Number of subjects: 486
Study 18834373 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol tartrate 100 mg (Betaloc) administered orally once to subjects in CYP2D6*1/*1 group
Number of subjects: 107
Study 18834373 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol tartrate 100 mg (Betaloc) administered orally once to subjects in CYP2D6*1/*10 group
Number of subjects: 107
Study 18834373 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol tartrate 100 mg (Betaloc) administered orally once to subjects in CYP2D6*10/*10 group
Number of subjects: 107
Study 16626345 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopy with chest tube insertion (Group I)
Number of subjects: 70
Study 16626345 — intervention group
Group type: COMPARATOR
Intervention: Tube thoracostomy without video-assisted thoracoscopy (Group II)
Number of subjects: 70
Study 12618639 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Care model (primary health care provided along with substance abuse treatment)
Number of subjects: 0
Study 12618639 — intervention group
Group type: COMPARATOR
Intervention: Independent Care model (medical care provided independently from substance abuse treatment)
Number of subjects: 0
Study 9973095 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal androgen blockade (MAB) treatment arm
Number of subjects: 0
Study 9973095 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex and flutamide
Number of subjects: 0
Study 9973095 — intervention group
Group type: COMPARATOR
Intervention: Control group (bilateral orchiectomy)
Number of subjects: 0
Study 7701173 — intervention group
Group type: EXPERIMENTAL
Intervention: Running therapy (twice a week for three months)
Number of subjects: 24
Study 2272007 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (n = 69): walking or jogging for 30 min, 3 times per week for one year
Number of subjects: 138
Study 2272007 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 69)
Number of subjects: 138
Study 6793418 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 8‐8427 (Phenoro) at a daily dose of 100 mg
Number of subjects: 50
Study 6793418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 29053219 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum (CG)
Number of subjects: 158
Study 29053219 — intervention group
Group type: COMPARATOR
Intervention: Non-chewing gum (NG)
Number of subjects: 158
Study 26682793 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 876
Study 26682793 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 876
Study 26682793 — intervention group
Group type: EXPERIMENTAL
Intervention: Both beta-blockers
Number of subjects: 876
Study 25831603 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride group (non-sucrose food supplement containing fluoride, 1,500 μg/l per dose)
Number of subjects: 228
Study 25831603 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-sucrose food supplement without fluoride)
Number of subjects: 228